Together, the merged companies would have nine pharmaceutical products with more than $1 billion in annual sales each. The deal is expected to be completed in the third quarter.
Together, the merged companies would have nine pharmaceutical products with more than $1 billion in annual sales each. The deal is expected to be completed in the third quarter.